相关实验视频

Updated: May 4, 2026

Application of Hemostatic Devices in Laparoscopic Hepatectomy

Application of Hemostatic Devices in Laparoscopic Hepatectomy

Published on: April 19, 2022

非常高的α-胎蛋白是否会影响接受肝切除术的早期肝细胞癌?

Hong-Shiue Chou^1,2, Chen-Fang Lee^1,2, Hao-Chien Hung^3,4

¹Division of Liver and Transplantation Surgery, Chang-Gung Memorial Hospital, Taoyuan, Taiwan.

Langenbeck's archives of surgery

|April 9, 2025

概括

高水平的α-fetoprotein (AFP) 在切除肝脏后不会影响早期肝细胞癌 (HCC) 患者的存活率. 对于这些HCC患者来说,无论AFP水平如何,治疗治疗应该优先考虑.

科学领域:

肝细胞癌研究肝细胞癌研究
手术瘤学手术瘤学
生物标记分析生物标记分析

背景情况:

肝切除 (LR) 后的复发显著影响肝细胞癌 (HCC) 的预后.
阿尔法-胎蛋白 (AFP) 的升高通常与HCC患者的不良结果和复发有关.
调查高AFP (>1,000 ng/ml) 在LR后早期HCC (BCLC第0期) 的预后值至关重要.

研究的目的:

评估高AFP水平对BCLC0期HCC患者的生存结果的影响.
在这个患者队列中确定影响生存和复发的临床病理因素.

主要方法:

对223名BCLC0期HCC患者的回顾性分析,这些患者在2004年至2012年期间接受了LR.
使用统计分析 (千平方,t测试,考克斯回归,卡普兰-梅尔) 的低AFP (n=200) 和高AFP (n=23) 的患者之间的结局比较.
评估临床病理学变量 (瘤大小,囊,肝硬化,HAI,微血管入侵) 与生存率之间的关联.

主要成果:

在低AFP和高AFP组之间,无病生存期 (DFS) 或总生存期 (OS) 没有显著差异 (p > 0.05).
两组之间临床病理学特征相似.
HCC复发与ICG R15,HAI得分和肝硬化有关,但与AFP水平无关.

结论:

在LR后,AFP水平不应影响BCLC0期HCC患者治愈意向治疗的时间.
建议对所有接受LR的0期HCC患者进行早期治疗,无论手术前的AFP水平如何.

关键词:

阿尔法-胎儿蛋白 (AFP) 是一种没有疾病的生存率 (DFS)肝细胞癌 (HCC) 是一种肝细胞癌.总体生存时间 (OS)部分肝脏切除部分肝脏切除

更多相关视频

Laparoscopic Anterior Right Hepatectomy: A Single-Center Experience

Laparoscopic Anterior Right Hepatectomy: A Single-Center Experience

Published on: December 4, 2023

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

相关概念视频

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...